Tag: anti-asthmatics and COPD drugs market analysis

  • What Will The Anti-Asthmatics And COPD Drugs Market Look Like In 2023?

    What Will The Anti-Asthmatics And COPD Drugs Market Look Like In 2023?

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

    The Business Research Company’s anti-asthmatics and COPD drugs market report forecasts the anti-asthmatics and COPD drugs market size to grow to $117.36 Billion by 2027, with a CAGR (compound annual growth rate) of more than 5%.

    Learn More On The Anti-Asthmatics And COPD Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

    Anti-Asthmatics And COPD Drugs Market Size Forecast
    The global anti-asthmatics and COPD drugs market is expected to grow from $88.20 billion in 2022 to $94.10 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anti-asthmatics and COPD drugs market size is expected to grow to $117.36 billion in 2027 at a CAGR of 5.7%.

    North America held the largest anti-asthmatics and COPD drugs market share, and Middle East was the fastest-growing region in 2022.

    Key Anti-Asthmatics And COPD Drugs Market Driver ­– Increase In Modifiable Risk Factors
    For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria by 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high-income countries including the USA and Europe. According to WHO, in developed countries, more than 35% of total energy requirement is derived from fats when compared to <20% in low-income countries, and <25% in lower-middle-income countries.

    Request for A Sample Of The Global Anti-Asthmatics And COPD Drugs Market Report:
    https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

    Key Anti-Asthmatics And COPD Drugs Market Trend – Adopting Combination Drugs For The Treatment Of Asthma And COPD
    This is due to the greater impact on patient-reported outcomes (PROs) compared to monotherapies. For example, a combination of short-acting beta-agonists (SABA) and short-acting muscarinic antagonists (SAMA) is superior compared to either medication alone in improving lung function. The use of a combination of long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA) have improved lung function than long-acting monotherapy bronchodilators.

    Anti-Asthmatics And COPD Drugs Market Segment
    1) By Type: Anti-histamine Drugs, long-acting ß2-agonists (LABA), Inhaled corticosteriods, Short-acting muscarinic receptor antagonists (SAMAs), Other Anti-Asthmatics And COPD Drugs (including Combinations)
    2) By Drug Class: Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
    3) By End User: Asthma Patients, COPD Patients
    4) By Distribution Channel: Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce

    Anti-Asthmatics And COPD Drugs Market Major Players and Strategies
    Major players in the anti-asthmatics and COPD drugs market are Novartis AG, Merck & Co., GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca, Roche, Teva Pharmaceutical, Vectura, Pfizer and Abbott.

    The Anti-Asthmatics And COPD Drugs Global Market Report 2023 covers regional data on anti-asthmatics and COPD drugs market size, anti-asthmatics and COPD drugs market trends and drivers, opportunities, strategies, and anti-asthmatics and COPD drugs market competitor analysis. The countries covered in the anti-asthmatics and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

    Anti-asthmatic and chronic obstructive pulmonary disease refers to drugs that are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

    View More Reports Related To The Anti-Asthmatics And COPD Drugs Market –
    Anti-Hypertensive Drugs Global Market Report 2023
    Anti-virals Global Market Report 2023
    Drugs For Erectile Dysfunction Global Market Report 2023

    Contact us at:
    The Business Research Company: https://www.thebusinessresearchcompany.com/
    Americas
    +1 3156230293
    Asia +44 2071930708
    Europe +44 2071930708
    Email us at info@tbrc.info

    Follow us on:
    LinkedIn:
    https://in.linkedin.com/company/the-business-research-company
    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
    Found this article helpful? Share it on:

  • Anti-Asthmatics And COPD Drugs Market Growth Potential: Key Insights for 2024-2033

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    How Will the Anti-Asthmatics And COPD Drugs Market Grow from 2024 to 2033?

    In recent times, the market for anti-asthmatics and COPD drugs has shown robust growth. The market is predicted to expand from $76.16 billion in 2023 to an impressive $81.41 billion in 2024, indicating a compound annual growth rate (CAGR) of 6.9%. Factors contributing to the growth during the historical period include a higher occurrence of respiratory ailments, an increase in tobacco smoking, the effects of global warming, an aging population, emerging markets, innovations in drug discovery techniques, and an overall rise in healthcare spending.

    In the upcoming years, the market for anti-asthmatics and COPD drugs is projected to experience substantial growth, reaching $104.1 billion by 2028 with a Compound Annual Growth Rate (CAGR) of 6.3%. Factors contributing to this projected growth include the rising popularity of e-cigarettes/vaping, escalating obesity rates, technological advancements, a considerable undiagnosed population, and the application of anti-asthmatics and COPD drugs in treating COVID-19 patients, as well as heightened consumption of fats. Future trends forecasted for the market encompass the production of probiotic drugs for varied treatment options for asthma, the development of Anti-IL-5 drugs to enhance business portfolios, the launch of innovative products targeting market positioning and competition sustainability. Furthermore, investments in bioelectric medicines for enhanced asthma treatment, focus on establishing more collaborations to enlarge business portfolios, venturing into personalized medicines aimed at offering individualized treatment, channelling funds towards the improvement of aerosol respiratory drugs efficacy, application of biomarkers for quicker drug production and exploring opportunities in generic drugs to deal with stiff market competition, it also includes the development of combination drugs for better outcomes, and, the creation of biologics to benefit from the increasing demand for biologic drugs.

    Claim Your Free Sample of the Global Anti-Asthmatics And COPD Drugs Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

    What Aspects Are Influencing the Growth Rate of the anti-asthmatics and copd drugs Market?

    Asthma and COPD drugs market progression is significantly influenced by changeable risk elements such as smoking, lack of physical workouts, and unhealthy diet. Even though a global decrease in smoking is witnessed, there is an upward trend in countries like China, India, Indonesia, and Nigeria. For example, it is predicted that tobacco smokers will rise by 24 million in Indonesia and 7 million in Nigeria by 2025, along with China being responsible for above 40% of global cigarette use. Furthermore, the consumption of fats, particularly saturated fatty acids known to be a risk factor for Asthma and COPD is notably high in developed countries including the USA and Europe. WHO reports highlight that in affluent countries, fat provides more than 35% of the total energy requirements in comparison to less than 20% in underprivileged countries, and below 25% in lower-middle-income nations.

    What Are the Critical Segments of the Anti-Asthmatics And COPD Drugs Market?

    1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs

    2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers

    3) By End User: Asthma Patients, COPD Patients

    4) By Therapy: Preventive, Curative

    5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous

    6) By Age Group: Below 5, 5-14, 15-60, Above 60

    What Trends Are Redefining Consumer Expectations in the Anti-Asthmatics And COPD Drugs Market?

    In the anti-asthmatics and COPD drugs market, leading companies are introducing innovative products like the fixed dose combination (FDC) drug, Indacaterol plus Mometasone, to enhance their market profitability. This FDC medication, delivered through the Breezhaler device, is intended for the daily management of asthma conditions. For example, in June 2022, Glenmark Pharmaceuticals, a company located in the US, unveiled a new fixed-dose combination (FDC) drug, Indacaterol plus Mometasone, geared towards patients with unmanageable asthma in India. This medication, promoted under the brand name, Indamet, is available in three different variations, with a standard dose of 150 mcg of Indacaterol and variable dosages of Mometasone, offered in 80 mcg, 160 mcg, and 320 mcg strengths.

    Order Now for Fast Delivery of Your Anti-Asthmatics And COPD Drugs Market Report!

    https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

    What Are the Leading Regions in the Anti-Asthmatics And COPD Drugs Market Expansion?

    North America was the largest region in the anti-asthmatics and COPD drugs market in 2023. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and copd drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    The Anti-Asthmatics And COPD Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the anti-asthmatics and copd drugs market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Anti-Asthmatics And COPD Drugs Market Include

    1. Anti-Asthmatics And COPD Drugs Market Executive Summary

    2. Anti-Asthmatics And COPD Drugs Market Segments

    3. Anti-Asthmatics And COPD Drugs Market Size And Template Market Growth Rate

    4. Key Anti-Asthmatics And COPD Drugs Market Trends

    5. Major Anti-Asthmatics And COPD Drugs Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market

    26. Top Anti-Asthmatics And COPD Drugs Companies

    27. Anti-Asthmatics And COPD Drugs Market Opportunities And Strategies

    28. Anti-Asthmatics And COPD Drugs Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Anti-Viral Drug Therapy Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/anti-viral-drug-therapy-market

    COVID-19 Drug Associated APIs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report

    Hospital Acquired Infections Testing Kits Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Key Insights On The Anti-Asthmatics And COPD Drugs Market 2024 – Size, Driver, And Major Players

    Key Insights On The Anti-Asthmatics And COPD Drugs Market 2024 – Size, Driver, And Major Players

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    As per The Business Research Company’s Anti-Asthmatics And COPD Drugs Global Market Report 2024, the anti-asthmatics and COPD drugs market is expected to show significant growth in the forecast period.

    The anti-asthmatics and COPD drugs market has witnessed significant growth in recent years. From $76.16 billion in 2023, it is projected to reach $81.41 billion in 2024, marking a notable compound annual growth rate (CAGR) of 6.9%. This growth can be attributed to several key factors:

    • Increased prevalence of respiratory diseases
    • Surge in tobacco smoking
    • Impact of global warming
    • Growing geriatric population
    • Emerging markets
    • Innovations in drug discovery methods
    • Rise in healthcare expenditure

    Future Projections

    Looking ahead, the market is poised for robust expansion. By 2028, it is estimated to soar to $104.1 billion, with a CAGR of 6.3%. Anticipated growth drivers include:

    • Rising popularity of e-cigarettes/vaping
    • Increasing obesity levels
    • Technological advancements
    • Large pool of undiagnosed population
    • Usage of anti-asthmatics and COPD drugs in COVID-19 treatment
    • Growing consumption of fats

    View More On The Anti-Asthmatics And COPD Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

    Modifiable Risk Factors Propel Anti-Asthmatics And COPD Drug Market

    Understanding the Driving Forces

    Modifiable risk factors such as smoking, sedentary lifestyles, and unhealthy dietary habits are significant contributors to the growth of the anti-asthmatics and COPD drugs market:

    • Despite a global decline in smoking rates, countries like China, India, Indonesia, and Nigeria are witnessing an upward trend.
    • High consumption of fats, particularly in developed nations like the USA and Europe, contributes to respiratory conditions.
    • WHO reports reveal stark differences in fat consumption across income groups, with developed countries exceeding recommended levels.

    Innovative FDC Drug Indacaterol Plus Mometasone Strengthens Leading Companies

    Advancements in Product Offerings

    Major players in the market are focusing on innovation to enhance their market position. One notable development is the introduction of Indacaterol plus Mometasone, a fixed-dose combination (FDC) drug:

    • Glenmark Pharmaceuticals launched Indacaterol plus Mometasone, designed for asthma management, showcasing the industry’s commitment to novel therapies.
    • This medication, available in various strengths, offers a convenient once-daily dosing regimen, catering to patient needs and preferences.

    Transitioning To Environmentally Friendly Inhalers

    Promoting Sustainability

    The shift towards environmentally friendly inhalers is gaining traction within the market:

    • Non-CFC inhalers are emerging as viable alternatives, aligning with global efforts to reduce environmental impact.
    • FDA regulations will play a crucial role in determining official alternatives, paving the way for eco-conscious healthcare practices.

    Market Segmentation and Regional Dynamics

    Understanding Market Segments

    The anti-asthmatics and COPD drugs market is segmented based on various criteria:

    • Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
    • Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
    • End User: Asthma Patients, COPD Patients
    • Therapy: Preventive, Curative
    • Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
    • Age Group: Below 5, 5-14, 15-60, Above 60

    Regional Insights

    • North America led the market in 2023, while the Middle East is poised for rapid growth during the forecast period.

    In conclusion, the anti-asthmatics and COPD drugs market is witnessing significant expansion driven by both current trends and future projections. With a focus on innovation, sustainability, and market segmentation, key players are poised to capitalize on emerging opportunities, shaping the future landscape of respiratory healthcare.

    Request A Sample Of The Global Anti-Asthmatics And COPD Drugs Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=3802&type=smp